Literature DB >> 2946761

Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis.

J Antel, M Bania, A Noronha, S Neely.   

Abstract

Activated suppressor cell function, induced with either concanavalin A or OKT3 and mediated by either unfractionated mononuclear cells or "panning" enriched T8+ cells, freshly isolated from peripheral blood, is reduced in patients with progressive multiple sclerosis (MS) as compared with control donors. In this study, we generated T8+ cell lines from the peripheral blood of these same patients and controls. Suppressor activity, mediated by T8+ cells exposed to OKT3 on days 1, 7, and 14 of culture and then treated with mitomycin C on day 16, was significantly reduced in the MS group (mean percent suppression 13% +/- 5) as compared with the control group (68% +/- 6, n = 8, p less than 0.001). No differences were noted in [3H]thymidine uptake by the OKT3-stimulated T8+ cell lines of MS and control groups. Mean percent suppression mediated by T4+ cell lines did not differ between MS and control groups (15% +/- 4, n = 3, vs 22% +/- 2, n = 4). These current data suggest that the previously observed defect in T8+ cell-mediated activated suppressor cell function in MS is a persistent one, favoring the postulate that the defect reflects intrinsic alterations in this cell population rather than a transient effect of serum factors on T8+ cell function.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2946761

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells.

Authors:  Khrishen Cunnusamy; Ethan J Baughman; Jorge Franco; Sterling B Ortega; Sushmita Sinha; Parul Chaudhary; Benjamin M Greenberg; Elliot M Frohman; Nitin J Karandikar
Journal:  Clin Immunol       Date:  2014-03-20       Impact factor: 3.969

Review 2.  Immune regulation of multiple sclerosis by CD8+ T cells.

Authors:  Sushmita Sinha; Farah R Itani; Nitin J Karandikar
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 3.  The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

Authors:  Andrew P Robinson; Christopher T Harp; Avertano Noronha; Stephen D Miller
Journal:  Handb Clin Neurol       Date:  2014

4.  Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis.

Authors:  Ethan J Baughman; Jason P Mendoza; Sterling B Ortega; Chris L Ayers; Benjamin M Greenberg; Elliot M Frohman; Nitin J Karandikar
Journal:  J Autoimmun       Date:  2011-01-22       Impact factor: 7.094

Review 5.  TCR peptide therapy in human autoimmune diseases.

Authors:  A A Vandenbark; E Morgan; R Bartholomew; D Bourdette; R Whitham; D Carlo; D Gold; G Hashim; H Offner
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

6.  Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.

Authors:  Nitin J Karandikar; Michael P Crawford; Xiao Yan; Robert B Ratts; Jason M Brenchley; David R Ambrozak; Amy E Lovett-Racke; Elliot M Frohman; Peter Stastny; Daniel C Douek; Richard A Koup; Michael K Racke
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

7.  Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis.

Authors:  K E Balashov; S J Khoury; D A Hafler; H L Weiner
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

8.  Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis.

Authors:  Arthur A Vandenbark; Nicole E Culbertson; Richard M Bartholomew; Jianya Huan; Marci Agotsch; Dorian LaTocha; Vijayshree Yadav; Michele Mass; Ruth Whitham; Jesus Lovera; June Milano; Georgia Theofan; Yuan K Chou; Halina Offner; Dennis N Bourdette
Journal:  Immunology       Date:  2007-10-16       Impact factor: 7.397

9.  Abnormal Tr1 differentiation in multiple sclerosis.

Authors:  Anne L Astier; David A Hafler
Journal:  J Neuroimmunol       Date:  2007-10-22       Impact factor: 3.478

Review 10.  Exploring the roles of CD8(+) T lymphocytes in the pathogenesis of autoimmune demyelination.

Authors:  Trina A Johnson; Frank R Jirik; Sylvie Fournier
Journal:  Semin Immunopathol       Date:  2010-03-18       Impact factor: 11.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.